Verona Pharma (VRNA)

• Market cap: $5.55B
• 1 day: -3.31%
• 5 days: -1.27%
• 1 month: 5.98%
• 3 months: 57.80%
• 6 months: 119.48%
• Year to date: 35.60%
• 1 year: 291.61%
• 5 years: 1,498.04%
• 10 years: 384.15%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Employees: 209

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

333% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 12

325% more call options, than puts

Call options by funds: $71.2M | Put options by funds: $16.7M

109% more funds holding in top 10

Funds holding in top 10: 11 [Q3] → 23 (+12) [Q4]

63% more capital invested

Capital invested by funds: $1.95B [Q3] → $3.19B (+$1.24B) [Q4]

27% more funds holding

Funds holding: 150 [Q3] → 190 (+40) [Q4]

0.07% more ownership

Funds ownership: 10.41% [Q3] → 10.48% (+0.07%) [Q4]

5% less repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 60

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $57 13% downside
• Avg. target: $73 12% upside
• High target: $93 42% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Tiago Fauth 39% 1-year accuracy 11 / 28 met price target	42% upside $93	Overweight Maintained	28 Feb 2025
HC Wainwright & Co. Raghuram Selvaraju 32% 1-year accuracy 109 / 342 met price target	15% upside $75	Buy Maintained	28 Feb 2025
Canaccord Genuity Edward Nash 55% 1-year accuracy 11 / 20 met price target	10% upside $72	Buy Maintained	12 Feb 2025
Roth MKM Boobalan Pachaiyappan 44% 1-year accuracy 4 / 9 met price target	4% upside $68	Buy Initiated	10 Jan 2025
Truist Securities Joon Lee 56% 1-year accuracy 24 / 43 met price target	13% downside $57	Buy Reiterated	8 Jan 2025